PMID- 37638405
OWN - NLM
STAT- MEDLINE
DCOM- 20240112
LR  - 20240202
IS  - 2831-090X (Electronic)
IS  - 2831-0896 (Print)
IS  - 2831-0896 (Linking)
VI  - 24
IP  - 1
DP  - 2024 Jan 3
TI  - Impact of the COVID-19 pandemic on management of surgically treated laryngeal 
      squamous cell carcinoma.
PG  - 188-195
LID - 10.17305/bb.2023.9481 [doi]
AB  - The coronavirus disease 2019 (COVID-19) pandemic has significantly impacted the 
      treatment of cancer patients, particularly in terms of treatment choices. This 
      study aimed to assess the effects of the COVID-19 pandemic on the management of 
      surgically treated laryngeal squamous cell carcinoma (LSCC) patients, focusing 
      specifically on changes in treatment modalities. We retrospectively analyzed the 
      data from 102 patients who underwent surgical treatment for LSCC between January 
      1, 2019, and December 31, 2021, at our tertiary medical center. Patient 
      demographics, histological characteristics, and treatment modalities were 
      extracted from electronic medical records and compared between two time periods: 
      pre-COVID-19 and during COVID-19, marked by the introduction of the hospital 
      entry triage. Of the total patients, 53 (52%) were in the pre-COVID-19 group, and 
      49 (48%) were in the COVID-19 group. No significant differences in patient 
      characteristics at the initial work-up were observed between the two groups. 
      However, a significant shift in treatment modalities was noted. Fewer patients 
      received postoperative adjuvant therapy in the COVID-19 group (70.5%) compared to 
      the pre-COVID-19 group (95.5%). Importantly, this change did not significantly 
      impact the one-year overall survival (OS) rates. The reduction in the use of 
      postoperative adjuvant therapy during the COVID-19 pandemic may be attributed to 
      efforts to minimize hospital visits due to the risk of COVID-19 infection. 
      Further research is warranted to validate these findings and to investigate the 
      potential effects of such changes in treatment modalities on the long-term 
      survival.
FAU - Lein, Alexander
AU  - Lein A
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of 
      Vienna, Vienna, Austria.
FAU - Liu, David T
AU  - Liu DT
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of 
      Vienna, Vienna, Austria.
FAU - Haas, Markus
AU  - Haas M
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of 
      Vienna, Vienna, Austria.
FAU - Salkic, Almir
AU  - Salkic A
AD  - Department of Otorhinolaryngology, University Clinical Center Tuzla, Tuzla, 
      Bosnia and Herzegovina.
FAU - Ibrisevic, Azra
AU  - Ibrisevic A
AD  - Department of Otorhinolaryngology, University Clinical Center Tuzla, Tuzla, 
      Bosnia and Herzegovina.
FAU - Uscuplic, Sabrina
AU  - Uscuplic S
AD  - Department of Otorhinolaryngology, University Clinical Center Tuzla, Tuzla, 
      Bosnia and Herzegovina.
FAU - Harcinovic, Alen
AU  - Harcinovic A
AD  - Department of Otorhinolaryngology, University Clinical Center Tuzla, Tuzla, 
      Bosnia and Herzegovina.
FAU - Brkic, Taria
AU  - Brkic T
AD  - Friedrich-Alexander University, Erlangen-Nuernberg, Germany.
FAU - Thurner, Thomas
AU  - Thurner T
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of 
      Vienna, Vienna, Austria.
FAU - Brkic, Faris F
AU  - Brkic FF
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of 
      Vienna, Vienna, Austria.
LA  - eng
PT  - Journal Article
DEP - 20240103
PL  - Bosnia and Herzegovina
TA  - Biomol Biomed
JT  - Biomolecules & biomedicine
JID - 9918522188506676
SB  - IM
MH  - Humans
MH  - Squamous Cell Carcinoma of Head and Neck/surgery
MH  - Pandemics
MH  - *Carcinoma, Squamous Cell/surgery
MH  - *Laryngeal Neoplasms/surgery
MH  - Retrospective Studies
MH  - *COVID-19/epidemiology
MH  - *Head and Neck Neoplasms
PMC - PMC10787613
COIS- Conflicts of interest: Authors declare no conflicts of interest.
EDAT- 2023/08/28 06:41
MHDA- 2024/01/12 06:42
PMCR- 2024/02/01
CRDT- 2023/08/28 05:26
PHST- 2023/07/05 00:00 [received]
PHST- 2023/08/24 00:00 [accepted]
PHST- 2024/01/12 06:42 [medline]
PHST- 2023/08/28 06:41 [pubmed]
PHST- 2023/08/28 05:26 [entrez]
PHST- 2024/02/01 00:00 [pmc-release]
AID - BB-24-188 [pii]
AID - 10.17305/bb.2023.9481 [doi]
PST - epublish
SO  - Biomol Biomed. 2024 Jan 3;24(1):188-195. doi: 10.17305/bb.2023.9481.